From Thomas Barnard at Seeking Alpha: Contribut
Post# of 36566
(Total Views: 378)
Posted On: 06/18/2019 8:49:01 AM
From Thomas Barnard at Seeking Alpha:
Contributor
Comments151 | + Follow
Author’s reply » The math that goes with the article above.
Immune Design's value is taken by the market at $300 million.
Generex owns 90% or more of NGIO after share dividend.
($300 mil/150 mil NGIO shrs) X .90 (150 mil) = the value of GNBT's NGIO shares = $270 mil
$270 million/60 million GNBT shares = $4.50.
This is the value of NGIO to be added to GNBT's share value.
The value of Generex if its NGIO shares were valued the same as Immune Design's shares as of today 6/17/2019 would be $1.70 + $4.50 = $6.20.
NEW | 17 Jun 2019, 11:59 PM Reply0Like
Thomas Barnard, Contributor
Comments151 | + Follow
Author’s reply » If NGIO (NuGenerex Immuno-Oncology) were listed, it might well be benefiting from the enthusiasm for cancer vaccine stocks. The above article posits the notion that GNBT, which owns 90+% of NGIO, should be $4 higher than where it currently trades.
www.marketwatch.com/...
Contributor
Comments151 | + Follow
Author’s reply » The math that goes with the article above.
Immune Design's value is taken by the market at $300 million.
Generex owns 90% or more of NGIO after share dividend.
($300 mil/150 mil NGIO shrs) X .90 (150 mil) = the value of GNBT's NGIO shares = $270 mil
$270 million/60 million GNBT shares = $4.50.
This is the value of NGIO to be added to GNBT's share value.
The value of Generex if its NGIO shares were valued the same as Immune Design's shares as of today 6/17/2019 would be $1.70 + $4.50 = $6.20.
NEW | 17 Jun 2019, 11:59 PM Reply0Like
Thomas Barnard, Contributor
Comments151 | + Follow
Author’s reply » If NGIO (NuGenerex Immuno-Oncology) were listed, it might well be benefiting from the enthusiasm for cancer vaccine stocks. The above article posits the notion that GNBT, which owns 90+% of NGIO, should be $4 higher than where it currently trades.
www.marketwatch.com/...
(0)
(0)